Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
Abstract Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the receptor‐mediated signaling of multiple...
Saved in:
Main Authors: | Martin E. Dowty (Author), Tsung H. Lin (Author), Michael I. Jesson (Author), Martin Hegen (Author), David A. Martin (Author), Vaibhav Katkade (Author), Sujatha Menon (Author), Jean‐Baptiste Telliez (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022) -
Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
by: A. E. Cheberda, et al.
Published: (2024) -
Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2024) -
Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation
by: Xiaolan Shen, et al.
Published: (2024) -
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
by: Qige Wei, et al.
Published: (2023)